Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioventus Inc BVS

Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products... see more

Recent & Breaking News (NDAQ:BVS)

Bioventus Reports Third Quarter Financial Results

GlobeNewswire November 5, 2024

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

GlobeNewswire October 29, 2024

Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

GlobeNewswire October 1, 2024

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

GlobeNewswire August 7, 2024

Bioventus Reports Second Quarter Financial Results

GlobeNewswire August 6, 2024

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024

GlobeNewswire July 30, 2024

Bioventus Reports First Quarter Financial Results

GlobeNewswire May 7, 2024

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

GlobeNewswire April 29, 2024

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 12, 2024

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

GlobeNewswire March 4, 2024

Grabar Law Office Investigates Claims on Behalf of Shareholders of Bioventus Inc. (BVS)

Newsfile January 24, 2024

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

GlobeNewswire January 18, 2024

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

GlobeNewswire January 12, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Bioventus Inc. and Encourages Long-Term BVS Investors to Contact the Firm - BVS

Newsfile January 8, 2024

BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire December 26, 2023

Bioventus Names Robert Claypoole as President and Chief Executive Officer

GlobeNewswire December 19, 2023

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Bioventus Inc. (NASDAQ: BVS) and Encourages Long-Term BVS Investors to Contact the Firm

Accesswire December 18, 2023

Bioventus Agrees to Nationwide Contract with Aetna(TM) Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

GlobeNewswire December 6, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Bioventus Inc.

Newsfile November 7, 2023

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

GlobeNewswire November 7, 2023